Results 131 to 140 of about 62,672 (281)

Pharmacovigilance [PDF]

, 2017
Michael Kaeding, Julia Schmälter, Christoph Klika   +2 more
  +4 more sources

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Pharmacovigilance

Journal of Drug Research in Ayurvedic Sciences, 2019
Sabrina Nour, Gilles Plourde
  +4 more sources

A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

Australian Veterinary Journal, EarlyView.
Clinical scenario Canine osteoarthritis (OA) is a degenerative joint disease and is one of the most common chronic conditions in dogs and other species. The management of OA remains a longstanding focus in veterinary medicine. Traditionally, nonsteroidal anti‐inflammatory drugs (NSAIDs) have been the first‐line treatment option for canine OA. Recently,
X Yang, P Macarthur
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Glycolytic metabolism of CD8+ T‐cells affects susceptibility to human leukocyte antigen‐mediated abacavir‐induced hypersensitivity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Drug hypersensitivity reactions (DHRs) associated with a specific human leukocyte antigen (HLA) allotype do not manifest uniformly in all individuals within an HLA model population. This scenario highlights the complexity of predicting drug hypersensitivity reaction risk without considering additional factors ...
Takeshi Susukida, Yuchen Sun, Noriaki Arakawa, Takuya Hirao, Tadahaya Mizuno, Shigeki Aoki, Kousei Ito, Yoshihiro Hayakawa   +7 more
wiley   +1 more source

Pharmacovigilance

Journal of the Royal College of Physicians of London, 1992
openaire   +2 more sources

Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use—A Scoping Review

Clinical &Experimental Allergy, EarlyView.
Rebound pruritus and urticaria have been reported after discontinuation of chronic cetirizine or levocetirizine use only. Symptoms typically occur within 0.5–5 days after stopping therapy and appear more frequently reported in female patients. Re‐initiation of antihistamines is the most commonly effective management strategy, highlighting the need for ...
Jun Jie Benjamin Seng, Prawira Oka, Ngiap Chuan Tan   +2 more
wiley   +1 more source

Limitations of FAERS‐based analyses of paternal drug exposure: The critical need for maternal data integration

Andrology, EarlyView.
Mikako Goto, Izumi Fujioka, Yasuha Ogawa, Sachi Koinuma, Koushi Yamaguchi   +4 more
wiley   +1 more source

Is There a Causal Link Between GLP‐1 Receptor Agonists and Non‐Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer, Joseph F. Rizzo III   +1 more
wiley   +1 more source